Monalizumab
Based on 5 publication(s) in Google Scholar
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.69%
- No. CAS: 1228763-95-8
- Peso molecular:146.3 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Monalizumab
More
Customer Validation & Images
-
Flow Cytometry
-
In Vivo Efficacy Study
-
ELISA
-
Flow Cytometry
-
Flow Cytometry
Actividad biológica
Human IgG4 kappa
Human
NKG2A/CD94
Monalizumab blocks NKG2A and enhances CLL NK-cell mediated cytotoxicity against HLA-E-expressing K562 cells[3].
Monalizumab enhances the Enzalutamide (HY-70002) (10 μM)-induced NK cell activation and killing of prostate cancer cells (LNCaP and 22Rv1)[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell[4]
-
Dosage:50 μg, together with 8 millions of activated NK cells
-
Administration:intratumoral injections
-
Result:Shows a synergestic antitumor effect.
Enhanced NK-cell killing, and induces lysis of tumor cells.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized NKG2A-CD94 Heterodimer Protein, Human (HEK293, His-Flag, HY-P70713) can bind Monalizumab. The EC50 for this effect is 4.83 ng/mL.
Chemical Information
-
No. CAS 1228763-95-8
-
Appearance Liquid
-
Peso molecular 146.3 kDa
-
Color Colorless to light yellow
-
SMILES
[Monalizumab]
-
Synonyms
IPH2201
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. [Abstract]2024 Jan 8;42(1):135-156.e17. PMID: 38101410
Monalizumab purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Jan 8;42(1):135-156.e17. [Abstract]
Flow cytometry panels demonstrating the expression level of NKG2A⁺, PD-1⁺Tim-3⁺, Granzyme B⁺ and IFN-γ⁺ in CD8⁺ tumor infiltrating T cells co-cultured with HLA-E⁺ tumor infiltrating B cells, either treated without Monalizumab (upper panel) or with Monalizumab (100 mg/mL; 20 h) (bottom panel).
-
J Immunother Cancer
2024 Jul 1; 12(7): e009410. PMID: 38955423
Monalizumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Jul 1; 12(7): e009410. [Abstract]
Degranulation of NKG2A+ KIR− NK cells after 4 hours of co-culture with untreated or 12 hours IFNγ-pretreated WT or HLA-E KO A375 cells in the presence of 5 µg/mL IgG1 or Monalizumab (mona) mAb (n=6).
Monalizumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Jul 1; 12(7): e009410. [Abstract]
Reduction in B2M KO cell population after 24 hours of co-culture of NK cells with mixed WT:B2M KO cells (1:1) at different E:T ratios in the presence of 5 µg/mL of indicated mAbs (Monalizumab (mona), etc.).
-
Cell Death Dis
Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma. [Abstract]2025 Nov 28;16(1):865. PMID: 41315184
Monalizumab purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Nov 28;16(1):865. [Abstract]
Healthy donor PBMCs were co-cultured with SKO-007 (J3) target cells, either untreated or treated with the indicated inhibitors for 48 h. NK cell degranulation assay was conducted at an Effector/Target (E/T) ratio of 2.5:1 in complete medium at 37 °C and 5% CO2 for 2 h. To assess the role of the NKG2A or KIR receptors, NK cells pretreated with blocking mAbs for NKG2A (Monalizumab,15 min) or IgG control were incubated with Pol I inhibitor-treated target cells.
-
Carcinogenesis
A2AR-phospho-STAT1 (Y701)-HLA-E axis as a potential immune modulatory pathway in radiotherapy-resistant triple negative breast cancer. [Abstract]2025 Oct 22:bgaf069. PMID: 41122851
Monalizumab purchased from MedChemExpress. Usage Cited in: Carcinogenesis. 2025 Oct 22:bgaf069. [Abstract]
Monalizumab (MNZ) (300 μg/100 μL/mouse; i.p.; once a week for five consecutive weeks). Body weights and tumor volumes were measured twice a week from the seventh day after injection of cancer cells.
Monalizumab purchased from MedChemExpress. Usage Cited in: Carcinogenesis. 2025 Oct 22:bgaf069. [Abstract]
Plasma perforin concentrations were determined by ELISA. The results showed that Monalizumab (MNZ) (300 μg/100 μL/mouse; i.p.; once a week for five consecutive weeks) treatment significantly increased perforin levels, which were lower in RT-R-MDA-MB-231-injected mice than in MDA-MB-231-injected mice.
-
Pureza y Documentación
-
Ficha de datos (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7(1):263. [Content Brief]
[2]. Christian Borel, et al. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2020 Sep 21;12(9):2691. [Content Brief]
[3]. McWilliams EM, et al. Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology. 2016 Sep 9;5(10):e1226720. [Content Brief]
[4]. Melero I, et al. Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies. EMBO Mol Med. 2023 Nov 8;15(11):e17804. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz